Chiron Optimistic About Re-entering U.S. Flu Vaccine Market In 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. Medicines & Healthcare Products Regulatory Agency extends suspension of Chiron's license to manufacture Fluvirin by three months, the company says. The extension can be "lifted at any time" once Chiron rectifies the problems at its Liverpool facility, MHRA says.
You may also be interested in...
Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.
Chiron Begins Fluvirin Manufacturing After U.K. Clears Site
The U.K. Medicines & Healthcare products Regulatory Agency lifts its suspension of Chiron's license to manufacture Fluvirin at its Liverpool facility. FDA says it will inspect the facility once "all the critical stages of manufacturing are in full swing."
Chiron Begins Fluvirin Manufacturing After U.K. Clears Site
The U.K. Medicines & Healthcare products Regulatory Agency lifts its suspension of Chiron's license to manufacture Fluvirin at its Liverpool facility. FDA says it will inspect the facility once "all the critical stages of manufacturing are in full swing."